NeoGenomics Inc (NEO)
NeoGenomics operate a network of cancer-focused testing laboratories in the U.S., Europe and Asia. Co.'s testing services include the following: Cytogenetics (karyotype analysis), a study of chromosomes and their relationship to disease; Fluorescence In-Situ Hybridization, a molecular cytogenetic technique that focuses on detecting and localizing the presence or absence of specific DNA sequences and genes on chromosomes; Flow cytometry, a technique utilized to measure the characteristics of cell populations; Immunohistochemistry and Digital Imaging; Molecular testing; and Morphologic analysis, a process of analyzing cells under the microscope.
NEO SEC Filing Email Alerts Service
Company Name: |
NeoGenomics Inc |
Website: |
www.neogenomics.com |
Sector: |
Diagnostics |
Number of ETFs Holding NEO: |
50 |
Total Market Value Held by ETFs: |
$406.54M |
Total Market Capitalization: |
$1.77B |
% of Market Cap. Held by ETFs: |
23.01% |
|
|
April 18, 2024 8:07 PM Eastern
Buy (3.42 out of 4)
100th percentile
|
|